Predicting Prostate Cancer Outcomes
Using Raman Imaging
H&E Stained Prostate Tissue
Raman Image of Unstained Prostate Tissue
Performed in collaboration with the Mayo Clinic and Allegheny General Hospital
Prostate cancer has a clinical course that is currently hard to predict. Some prostate cancers are indolent, slow growing, and would require little or no intervention, while other prostate cancers require aggressive medical treatment. Sometimes cases that appear identical based on biopsy can actually have very different outcomes.
In some of those cases, ChemImage’s Raman Molecular Imaging (RMI) approach enables the discrimination of samples from patients who go on to develop aggressive metastatic disease from those who do not. This can help surgeons and oncologists develop more accurate treatment protocols.
Raman Molecular Imaging Of Prostate Cancers Can Provide:
- Chemometric analysis and classification of cells
- A clear discrimination between slow growing and aggressive carcinomas
- Molecular-specific information displayed in the familiar format of a digital image
- Non-destructive analysis of cells
Raman molecular images are acquired from tissue samples illuminated by a laser in a microscope. The images are analyzed using chemometric-based classification algorithms to determine whether the disease may become metastatic at some point in the future—a predictive outcome that’s been verified in early studies with the Mayo Clinic.